Monte Rosa Therapeutics Inc
GLUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.13B
Close$
$24.78
74.3% upside
Current Fair Value
74.3% upsideUndervalued by 74.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.13 Billion |
|---|---|
| Enterprise Value | $1.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.59 |
| Beta | 1.53 |
| Outstanding Shares | 85,226,427 |
Return
| Return on Equity | -33.06% |
|---|---|
| Return on Assets | -23.15% |
| Return on Invested Capital | -27.96% |
Valuation & Multiples
| P/E Ratio | -6.14 |
|---|---|
| PEG | -2.43 |
| Price to Sales | - |
| Price to Book Ratio | 2.84 |
| Enterprise Value to Revenue | 38.3 |
| Enterprise Value to EBIT | -6.25 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$12.91 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$18.89 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0978▼ 26.90% |
|---|---|
| Total Calls | 535,934▲ 157.29% |
| Total Puts | 52,400▼ 31.41% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 144.24%▲ 11.58% |
|---|---|
| Total Invested | $2.31B▲ 61.48% |
| Investors Holding | 202▲ 6.00% |
ESG Score
No data
About Monte Rosa Therapeutics Inc
60 employees